Active Biotech, a Sweden-based biopharmaceutical company that is developing therapies for autoimmune diseases, inflammatory diseases, and cancers, recently announced that it is partnering with Teva Pharmaceutical Industries Ltd. to develop a new, experimental drug for treating Huntington’s disease. The two companies will work together to launch a new phase 2 clinical trial…
Teva, Active Biotech Partner To Develop Laquinimod For Huntington’s Disease
Nonsense mutation Duchenne muscular dystrophy (nmDMD) patients living in the European Union may soon experience relief from their condition due to the European Commission granting PTC Therapeutics, Inc. conditional marketing for Translarna™ (ataluren). PTC Therapeutics may now market Translarna in the 28 Member States of…
Recent Posts
- Longer NFL careers tied to higher ALS and neurodegenerative death rates
- ALS and wildfire smoke remind me there’s only so much I can control
- Chinese study connects past smoking habits to increased risk for ALS
- Researcher honored for AI brain implant that helps restore speech in ALS
- Early ALS trial finds therapy well tolerated and lowers disease markers